webinar register page

Strategic Planning for Orphan Drugs: Maximizing Asset Value Through Evidence Generation Planning
When developing new products to treat rare diseases, it is particularly challenging to demonstrate product value that is sufficient to support successful reimbursement and patient access.

Creating a strategic plan with a Market Access Evidence Roadmap can help you identify areas of evidence generation required to support reimbursement and increase patient access to your product.

What you will learn during this 1-hour session:
• What are Market Access Evidence Roadmaps
o Their critical role in developing a reimbursement strategy for orphan drugs
o How they are developed and applied
• The HTA requirements in key markets
• Innovative or alternative funding mechanisms for orphan drugs for selected markets and how to plan to access them

This webinar is ideal for those who are new to—or unfamiliar with—the increasing use and relevance of evidence generation for market access in early pharmaceutical development to support future reimbursement.

Who should attend:
• Small- to medium-sized pharmaceutical companies
• Companies wishing to prepare for acquisition
• Companies pursuing licensing for their product
• Pharmaceutical companies in orphan drug development.

Jun 7, 2022 10:00 AM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: RTI Health Solutions.